PD1 Non-Small Cell Lung Cancer Treatment Market Size, Share, Growth, and Industry Analysis, By Types (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, ), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, ) , and Regional Insights and Forecast to 2035

Table of Content



1 Market Overview

1.1 Product Definition and Market Characteristics

1.2 Global PD1 Non-Small Cell Lung Cancer Treatment Market Size

1.3 Market Segmentation

1.4 Regulatory Environment



2 Industry Chain Analysis

2.1 Industry Chain Analysis

2.2 PD1 Non-Small Cell Lung Cancer Treatment Raw Materials Analysis

2.2.1 Key Raw Materials Introduction

2.2.2 Key Suppliers of Raw Materials

2.3 PD1 Non-Small Cell Lung Cancer Treatment Business Mode and Production Process

2.3.1 PD1 Non-Small Cell Lung Cancer Treatment Business Mode Analysis

2.3.2 Production Process Analysis

2.4 PD1 Non-Small Cell Lung Cancer Treatment Cost Structure Analysis

2.4.1 Manufacturing Cost Structure of PD1 Non-Small Cell Lung Cancer Treatment

2.4.2 Raw Material Cost of PD1 Non-Small Cell Lung Cancer Treatment

2.4.3 Labor Cost of PD1 Non-Small Cell Lung Cancer Treatment

2.5 Market Channel Analysis

2.6 Major Downstream Customers Analysis

2.7 Alternative Product Analysis



3 Market Dynamics

3.1 Market Drivers

3.2 Market Constraints and Challenges

3.3 Emerging Market Trends

3.4 PESTEL Analysis

3.5 Consumer Insights Analysis

3.6 Impact of Russia and Ukraine War



4 Market Competitive Landscape

4.1 Global PD1 Non-Small Cell Lung Cancer Treatment Revenue and Market Share by Manufacturer (2021-2026)

4.2 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume and Market Share by Manufacturer (2021-2026)

4.3 Global PD1 Non-Small Cell Lung Cancer Treatment Price by Manufacturer (2021-2026)

4.4 PD1 Non-Small Cell Lung Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

4.5 Global Key Manufacturers of PD1 Non-Small Cell Lung Cancer Treatment, Manufacturing Base Distribution and Headquarters

4.6 Global Key Manufacturers of PD1 Non-Small Cell Lung Cancer Treatment, Product Offered and Application

4.7 PD1 Non-Small Cell Lung Cancer Treatment Market Competitive Situation and Trends

4.7.1 PD1 Non-Small Cell Lung Cancer Treatment Market Concentration Rate

4.7.2 Global Top 3 and Top 6 PD1 Non-Small Cell Lung Cancer Treatment Players Market Share by Revenue

4.8 Industry News

4.8.1 Key Product Launch News

4.8.2 Mergers & Acquisitions, Expansion Plans



5 Global PD1 Non-Small Cell Lung Cancer Treatment Market Historical Development by Geographic Region (2021-2026)

5.1 Global PD1 Non-Small Cell Lung Cancer Treatment Market Historical Sales Volume by Geographic Region (2021-2026)

5.2 Global PD1 Non-Small Cell Lung Cancer Treatment Market Historical Revenue by Geographic Region (2021-2026)

5.3 North America PD1 Non-Small Cell Lung Cancer Treatment Market Status by Country (2021-2026)

5.3.1 North America PD1 Non-Small Cell Lung Cancer Treatment Sales Volume by Country (2021-2026)

5.3.2 North America PD1 Non-Small Cell Lung Cancer Treatment Revenue by Country (2021-2026)

5.3.3 United States PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.3.4 Canada PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4 Europe PD1 Non-Small Cell Lung Cancer Treatment Market Status by Country (2021-2026)

5.4.1 Europe PD1 Non-Small Cell Lung Cancer Treatment Sales Volume by Country (2021-2026)

5.4.2 Europe PD1 Non-Small Cell Lung Cancer Treatment Revenue by Country (2021-2026)

5.4.3 Germany PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4.4 France PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4.5 United Kingdom PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4.6 Spain PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4.7 Russia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.4.8 Poland PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5 Asia Pacific PD1 Non-Small Cell Lung Cancer Treatment Market Status by Country (2021-2026)

5.5.1 Asia Pacific PD1 Non-Small Cell Lung Cancer Treatment Sales Volume by Country (2021-2026)

5.5.2 Asia Pacific PD1 Non-Small Cell Lung Cancer Treatment Revenue by Country (2021-2026)

5.5.3 China PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5.4 Japan PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5.5 South Korea PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5.6 Southeast Asia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5.7 India PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.5.8 Australia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.6 Latin America PD1 Non-Small Cell Lung Cancer Treatment Market Status by Country (2021-2026)

5.6.1 Latin America PD1 Non-Small Cell Lung Cancer Treatment Sales Volume by Country (2021-2026)

5.6.2 Latin America PD1 Non-Small Cell Lung Cancer Treatment Revenue by Country (2021-2026)

5.6.3 Mexico PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.6.4 Brazil PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.7 Middle East and Africa PD1 Non-Small Cell Lung Cancer Treatment Market Status by Country (2021-2026)

5.7.1 Middle East and Africa PD1 Non-Small Cell Lung Cancer Treatment Sales Volume by Country (2021-2026)

5.7.2 Middle East and Africa PD1 Non-Small Cell Lung Cancer Treatment Revenue by Country (2021-2026)

5.7.3 GCC PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)

5.7.4 South Africa PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue and Growth (2021-2026)



6 Global PD1 Non-Small Cell Lung Cancer Treatment Market Historical Development by Product Type (2021-2026)

6.1 PD1 Non-Small Cell Lung Cancer Treatment Definition by Type

6.2 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume by Product Type (2021-2026)

6.3 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Revenue by Product Type (2021-2026)

6.4 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Price by Product Type (2021-2026)

6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2021-2026)

6.5.1 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Nivolumab (2021-2026)
6.5.2 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Pembrolizumab (2021-2026)
6.5.3 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Atezolizumab (2021-2026)
6.5.4 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Avelumab (2021-2026)
6.5.5 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Durvalumab (2021-2026)


7 Global PD1 Non-Small Cell Lung Cancer Treatment Market Historical Development by End User (2021-2026)

7.1 Downstream Market Overview

7.2 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume by End User (2021-2026)

7.3 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Revenue by End User (2021-2026)

7.4 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Price by End User (2021-2026)

7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2021-2026)

7.5.1 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Hospital Pharmacies (2021-2026)
7.5.2 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Retail Pharmacies (2021-2026)
7.5.3 Global PD1 Non-Small Cell Lung Cancer Treatment Historical Sales Volume, Revenue and Growth Rate of Online Pharmacies (2021-2026)


8 Leading Companies Profiles

8.1 Novartis AG
8.1.1 Novartis AG Corporation Information
8.1.2 Novartis AG - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.1.3 Novartis AG Performance Analysis (2021-2026)
8.1.4 Novartis AG Business and Markets Served
8.1.5 Novartis AG Recent Developments
8.2 Bristol-Myers Squibb
8.2.1 Bristol-Myers Squibb Corporation Information
8.2.2 Bristol-Myers Squibb - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.2.3 Bristol-Myers Squibb Performance Analysis (2021-2026)
8.2.4 Bristol-Myers Squibb Business and Markets Served
8.2.5 Bristol-Myers Squibb Recent Developments
8.3 F. Hoffmann-La Roche AG
8.3.1 F. Hoffmann-La Roche AG Corporation Information
8.3.2 F. Hoffmann-La Roche AG - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.3.3 F. Hoffmann-La Roche AG Performance Analysis (2021-2026)
8.3.4 F. Hoffmann-La Roche AG Business and Markets Served
8.3.5 F. Hoffmann-La Roche AG Recent Developments
8.4 Sanofi
8.4.1 Sanofi Corporation Information
8.4.2 Sanofi - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.4.3 Sanofi Performance Analysis (2021-2026)
8.4.4 Sanofi Business and Markets Served
8.4.5 Sanofi Recent Developments
8.5 Takeda Pharmaceutical Company Limited
8.5.1 Takeda Pharmaceutical Company Limited Corporation Information
8.5.2 Takeda Pharmaceutical Company Limited - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.5.3 Takeda Pharmaceutical Company Limited Performance Analysis (2021-2026)
8.5.4 Takeda Pharmaceutical Company Limited Business and Markets Served
8.5.5 Takeda Pharmaceutical Company Limited Recent Developments
8.6 Eli Lilly and Company
8.6.1 Eli Lilly and Company Corporation Information
8.6.2 Eli Lilly and Company - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.6.3 Eli Lilly and Company Performance Analysis (2021-2026)
8.6.4 Eli Lilly and Company Business and Markets Served
8.6.5 Eli Lilly and Company Recent Developments
8.7 GlaxoSmithKline Plc.
8.7.1 GlaxoSmithKline Plc. Corporation Information
8.7.2 GlaxoSmithKline Plc. - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.7.3 GlaxoSmithKline Plc. Performance Analysis (2021-2026)
8.7.4 GlaxoSmithKline Plc. Business and Markets Served
8.7.5 GlaxoSmithKline Plc. Recent Developments
8.8 Agennix AG
8.8.1 Agennix AG Corporation Information
8.8.2 Agennix AG - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.8.3 Agennix AG Performance Analysis (2021-2026)
8.8.4 Agennix AG Business and Markets Served
8.8.5 Agennix AG Recent Developments
8.9 Merck Co. & Inc.
8.9.1 Merck Co. & Inc. Corporation Information
8.9.2 Merck Co. & Inc. - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.9.3 Merck Co. & Inc. Performance Analysis (2021-2026)
8.9.4 Merck Co. & Inc. Business and Markets Served
8.9.5 Merck Co. & Inc. Recent Developments
8.10 Pfizer Inc.
8.10.1 Pfizer Inc. Corporation Information
8.10.2 Pfizer Inc. - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.10.3 Pfizer Inc. Performance Analysis (2021-2026)
8.10.4 Pfizer Inc. Business and Markets Served
8.10.5 Pfizer Inc. Recent Developments
8.11 AstraZeneca Plc.
8.11.1 AstraZeneca Plc. Corporation Information
8.11.2 AstraZeneca Plc. - PD1 Non-Small Cell Lung Cancer Treatment Product Portfolio and Specification
8.11.3 AstraZeneca Plc. Performance Analysis (2021-2026)
8.11.4 AstraZeneca Plc. Business and Markets Served
8.11.5 AstraZeneca Plc. Recent Developments


9 Global PD1 Non-Small Cell Lung Cancer Treatment Market Forecast by Product Type and End User (2026-2034)

9.1 Global PD1 Non-Small Cell Lung Cancer Treatment Market Forecast by Product Type (2026-2034)

9.1.1 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Nivolumab (2026-2034)
9.1.2 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Pembrolizumab (2026-2034)
9.1.3 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Atezolizumab (2026-2034)
9.1.4 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Avelumab (2026-2034)
9.1.5 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Durvalumab (2026-2034)
9.2 Global PD1 Non-Small Cell Lung Cancer Treatment Market Forecast by End User (2026-2034)

9.2.1 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Hospital Pharmacies (2026-2034)
9.2.2 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Retail Pharmacies (2026-2034)
9.2.3 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth Rate of Online Pharmacies (2026-2034)


10 Global PD1 Non-Small Cell Lung Cancer Treatment Market Forecast by Geographic Region (2026-2034)

10.1 Global PD1 Non-Small Cell Lung Cancer Treatment Sales Volume and Revenue Forecast by Geographic Region (2026-2034)

10.2 North America PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.2.1 United States PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.2.2 Canada PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3 Europe PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.1 Germany PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.2 France PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.3 United Kingdom PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.4 Spain PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.5 Russia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.3.6 Poland PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4 Asia Pacific PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.1 China PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.2 Japan PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.3 South Korea PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.4 Southeast Asia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.5 India PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.4.6 Australia PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.5 Latin America PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.5.1 Mexico PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.5.2 Brazil PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.6 Middle East and Africa PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.6.1 GCC PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)

10.6.2 South Africa PD1 Non-Small Cell Lung Cancer Treatment Sales Volume, Revenue Forecast and Growth (2026-2034)



11 Appendix

11.1 Methodology

11.2 Research Data Source

11.2.1 Secondary Data

11.2.2 Primary Data

11.2.3 Market Size Estimation

11.2.4 Legal Disclaimer